Cediranib (AZD2171)

Cediranib (AZD2171) is an inhibitor of VEGFR and FGFR1 and related targets used in studies of MAPK / ERK Signaling. It is especially relevant in angiogenesis, cancer, and cell signaling models, where defined compound exposure can be linked to mitogenic kinase cascades, proliferation control, and differentiation-linked signaling.

By inhibiting VEGFR and FGFR1 and related targets, Cediranib (AZD2171) can be used to examine mitogenic kinase cascades, proliferation control, and differentiation-linked signaling. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In angiogenesis, cancer, and cell signaling models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving VEGFR and FGFR1 and related targets
• Pathway perturbation studies connected to MAPK / ERK Signaling
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, Cediranib (AZD2171) is appropriate when a defined chemical perturbant is needed to connect VEGFR and FGFR1 and related targets with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in angiogenesis, cancer, and cell signaling models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.